MIM
SGP

Monashee Investment Management’s SpyGlass Pharma SGP Stock Holding History

Monashee Investment Management’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-95,000
Closed -$2.46M – 57
2026
Q1 		$2.46M Buy
+95,000
New +$2.56M 1.34% 25

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Monashee Investment Management's SGP Position: Q2 2026 in Review

Monashee Investment Management sold out of SpyGlass Pharma (SGP) in Q2 2026, closing a stake of 95,000 shares — an estimated $2.46M sold.

Monashee Investment Management first reported a position in SGP in Q1 2026 and held it in 1 quarter. The position peaked at $2.46M in Q1 2026. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Monashee Investment Management reported no remaining SpyGlass Pharma position as of Q2 2026 after selling out during the quarter.
  • Monashee Investment Management sold 95,000 SpyGlass Pharma shares in Q2 2026, an estimated $2.46M.
  • Monashee Investment Management first reported a position in SpyGlass Pharma in Q1 2026 and held it in 1 quarter.
  • Monashee Investment Management's SpyGlass Pharma position peaked at $2.46M in Q1 2026.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Monashee Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.